Sangamo BioSciences Stock Rating Upgraded by Thomson Reuters/Verus (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) was upgraded by analysts at Thomson Reuters/Verus from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, ARN reports.
Shares of Sangamo BioSciences (NASDAQ:SGMO) traded down 1.43% during mid-day trading on Monday, hitting $11.03. The stock had a trading volume of 176,789 shares. Sangamo BioSciences has a 1-year low of $4.92 and a 1-year high of $13.20. The stock’s 50-day moving average is $10.84 and its 200-day moving average is $9.49. The company’s market cap is $596.8 million.
Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, July 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $4.77 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. On average, analysts predict that Sangamo BioSciences will post $-0.43 earnings per share for the current fiscal year.
Separately, analysts at Zacks upgraded shares of Sangamo BioSciences from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 30th. They now have a $10.50 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $16.70.
In other Sangamo BioSciences news, VP Philip D. Gregory sold 15,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.54, for a total transaction of $158,100.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.